Dr. Ron’s Research Review – April 8, 2015

©                                                                                                                 

This week’s research review focuses on Strontium safety

The data shows a larger proportion of patients with cardiac disorders in the strontium ranelate 2g group compared to placebo; especially for ischemic cardiac events.

Cardiovascular disorders

 

Post-menopausal osteoporosis

Male osteoporosis

Osteoarthritis

SrRan 2g

7.97%

5.53%

3.24%

Placebo

6.58%

4.17%

1.21%

A closer examination of table 2, however, shows a protective effect of Strontium ranelate at lower doses (up to 1 gram).

Table 2: Cardiovascular disorders

 

Post-menopausal osteoporosis

Male osteoporosis

Osteoarthritis

SrRan 0.125g

10%

 

 

SrRan 0.5g

15.20%

 

 

SrRan 1g

14.62%

 

18.07%

SrRan 2g

31.31%

24.68%

17.92%

SrRan All

30.5%

24.68%

17.99%

Placebo

29.17%

28.13%

18.20%

The European Medicines Agency (EMA) recommends the following contra-indications should be added:
“Established, current or past history of ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.
Uncontrolled hypertension.”
The following warning should be added:
“Cardiac ischaemic events

Dr. Ron


Articles

 

European Medicines Agency PSUR assessment report: Strontium ranelate
            (EMA, 2013) Download

References

EMA. (2013). European Medicines Agency PSUR assessment report: Strontium ranelate. Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000560/WC500147168.pdf